Wall Street Zen Downgrades Maze Therapeutics (NASDAQ:MAZE) to Sell

Maze Therapeutics (NASDAQ:MAZE) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

MAZE has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Mizuho raised Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Wedbush raised their price objective on Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Truist Financial cut their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. Finally, BTIG Research reissued a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Price Performance

MAZE opened at $28.09 on Friday. Maze Therapeutics has a fifty-two week low of $7.16 and a fifty-two week high of $53.65. The business has a 50-day moving average of $40.60 and a 200-day moving average of $38.29. The company has a market capitalization of $1.40 billion, a PE ratio of -8.70 and a beta of 5.16.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, January 29th. The stock was sold at an average price of $44.27, for a total value of $332,025.00. Following the sale, the insider owned 10,503 shares of the company’s stock, valued at $464,967.81. This trade represents a 41.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CMO Harold Bernstein sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $29.46, for a total value of $441,900.00. Following the completion of the sale, the chief marketing officer directly owned 15,000 shares in the company, valued at $441,900. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 95,000 shares of company stock valued at $4,245,625 in the last 90 days.

Institutional Trading of Maze Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MAZE. Royal Bank of Canada grew its holdings in Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Maze Therapeutics in the 4th quarter valued at approximately $39,000. Ameritas Investment Partners Inc. grew its holdings in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics in the 4th quarter valued at approximately $43,000. Finally, Russell Investments Group Ltd. grew its holdings in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after buying an additional 1,725 shares during the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.